Median platelet count by use of concomitant ITP medication in the LTE
| Observed platelet count, median, ×109/L . | Rilzabrutinib monotherapy (n = 5) . | Rilzabrutinib + concomitant ITP medication (n = 11) . |
|---|---|---|
| Main treatment period, baseline | 21 | 18 |
| At LTE entry | 68 | 156 |
| At LTE 3 mo | 90 | 94 |
| At LTE 6 mo | 73 | 66 |
| Observed platelet count, median, ×109/L . | Rilzabrutinib monotherapy (n = 5) . | Rilzabrutinib + concomitant ITP medication (n = 11) . |
|---|---|---|
| Main treatment period, baseline | 21 | 18 |
| At LTE entry | 68 | 156 |
| At LTE 3 mo | 90 | 94 |
| At LTE 6 mo | 73 | 66 |